Quote
Email Us
Who We Are

About Us

Trusted by 300,000+ scientists and industry leaders for integrated DNA/RNA manufacturing solutions.

Who We Are

Tsingke Biotech is a leading biotechnology company providing gene synthesis, oligonucleotide manufacturing, and integrated life science solutions.

With over 20 years of expertise and a nationwide operational network, we deliver end-to-end capabilities — from raw material production to GMP-ready nucleic acid manufacturing — serving both scientific research and industrial applications.

Trusted by over 300,000 customers worldwide, including academic institutions, biotech companies, diagnostics developers, and pharmaceutical manufacturers, Tsingke is committed to enabling breakthroughs in research, diagnostics, and therapeutics.

Mission & Vision

Mission & Vision
Mission & Vision
Mission

Biotech for a Better World — driving scientific innovation through advanced nucleic acid manufacturing.

Mission & Vision
Vision

The Great Tsingke Gene Factory — building the most integrated and efficient global platform for DNA/RNA synthesis.

Milestones

2002
2002

Founders began entrepreneurship in nucleic acid synthesis.

2002
2002

Founders began entrepreneurship in nucleic acid synthesis.

2007
2007

Entered chemical raw material production.

2007
2007

Entered chemical raw material production.

2010
2010

Expanded into gene detection services.

2010
2010

Expanded into gene detection services.

2011
2011

Launched oligonucleotide synthesis and modifications.

2011
2011

Launched oligonucleotide synthesis and modifications.

2013
2013

Developed self-owned synthesis instruments.

2013
2013

Developed self-owned synthesis instruments.

2016
2016

Began molecular reagent production.

2016
2016

Began molecular reagent production.

2017
2017

Founded Beijing Tsingke Biotechnology Co., Ltd.; launched gene synthesis business.

2017
2017

Founded Beijing Tsingke Biotechnology Co., Ltd.; launched gene synthesis business.

2021
2021

Completed Series A financing (RMB 150 million).

2021
2021

Completed Series A financing (RMB 150 million).

2022
2022

Completed Series B financing (RMB 400 million); launched nucleic acid drug platform

2022
2022

Completed Series B financing (RMB 400 million); launched nucleic acid drug platform

2023
2023

Corporate restructuring to Beijing Tsingke Biotechnology Co., Ltd. (Joint Stock).

2023
2023

Corporate restructuring to Beijing Tsingke Biotechnology Co., Ltd. (Joint Stock).

Scale Capability

Scale Capability

Tsingke's operations are strategically distributed 

across China to support the Gene Factory concept

BJ
BJ

BJ
TJ
TJ

TJ
HB
HB

HB
JN

JN
QD

QD
XA

XA
ZJ

ZJ
NJ
NJ

NJ
HB
HB

HB
SZ
SZ

SZ
SH

SH
HZ

HZ
CD

CD
CQ

CQ
CS

CS
FZ

FZ
KM

KM
NN

NN
GZ

GZ
HK

HK
Contact Us
Explore the power of the Gene Factory and discover how Tsingke's integrated platform accelerates your R&D and product development.
Tsingke Updates
pop_close
pop_main
Subscribe to Our Newsletter

Stay updated with the latest industry news and expert insights. 

Subscribe now to receive:
        ● Industry updates
        ● Exclusive expert insights and analysis
Enter your email to stay ahead!

We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. Part of the tracking is necessary to ensure SEO effectiveness,
By using this site, you agree to our use of cookies. Visit our cookie policy to learn more.
Reject Accept